Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)

Lundbeck

Status and phase: Terminated; Phase 3

Conditions: Primary Insomnia

Treatments: Drug: MK0928, gaboxadol / Duration of Treatment - 6 weeks; Drug: Comparator: placebo / Duration of Treatment - 6 weeks

Study type: Interventional

Funder types: Industry

Identifiers

NCT00094666

MK0928-002

2004_085

0928-002

Details and patient eligibility

About

The purpose of the study is to test the safety and effectiveness of an Investigational Drug on insomnia in the elderly.

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Elderly patients with a diagnosis of primary insomnia and in good physical and mental health

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind